Literature DB >> 18522305

Influenza viruses with reduced sensitivity to the neuraminidase inhibitor drugs in untreated young children.

Aeron C Hurt1, Ian G Barr.   

Abstract

The neuraminidase inhibitors are a class of antiviral drugs used for both the prophylaxis and treatment of influenza infections. Clinical trials of these inhibitors detected a low level of resistant viruses from treated individuals, although a higher frequency was detected in children (5%-6%) compared to adults (1%-4%). In addition, there have been some previous reports of NA inhibitor resistant viruses being isolated from untreated individuals. Here we report on the NA inhibitor sensitivity of over 1,000 influenza isolates collected through the World Health Organization (WHO) global influenza surveillance program. Of the total number of viruses analysed, only 2 (0.2%) strains (an A(H1N1) strain and an influenza B strain) were considered to have a significant reduction in sensitivity to at least one of the neuraminidase inhibitor drugs. Interestingly, both of these strains were isolated from untreated patients in the youngest age cohort (less than 2 years). Although the influenza B strain is unlikely to be clinically resistant, the A(H1N1) virus contained the same His274Tyr neuraminidase mutation that has been observed in resistant mutants following oseltamivir treatment. Given these results it may be important to enhance neuraminidase inhibitor susceptibility testing of viruses from patients in the less than two years cohort.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18522305

Source DB:  PubMed          Journal:  Commun Dis Intell Q Rep        ISSN: 1447-4514


  11 in total

1.  In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.

Authors:  Aeron C Hurt; Jessica K Holien; Ian G Barr
Journal:  Antimicrob Agents Chemother       Date:  2009-08-03       Impact factor: 5.191

2.  A near-fatal infection with oseltamivir-resistant seasonal influenza A in a previously healthy child: Case report.

Authors:  Jesse Papenburg; Christos Karatzios; Yan Li; Nathalie Bastien; Makeda Semret; Dorothy Moore
Journal:  Can J Infect Dis Med Microbiol       Date:  2009       Impact factor: 2.471

Review 3.  Systematic review of influenza resistance to the neuraminidase inhibitors.

Authors:  Kristian Thorlund; Tahany Awad; Guy Boivin; Lehana Thabane
Journal:  BMC Infect Dis       Date:  2011-05-19       Impact factor: 3.090

4.  Influenza outbreaks during World Youth Day 2008 mass gathering.

Authors:  Christopher C Blyth; Hong Foo; Sebastiaan J van Hal; Aeron C Hurt; Ian G Barr; Kenneth McPhie; Paul K Armstrong; William D Rawlinson; Vicky Sheppeard; Stephen Conaty; Michael Staff; Dominic E Dwyer
Journal:  Emerg Infect Dis       Date:  2010-05       Impact factor: 6.883

5.  Pharmacokinetics of Oral and Intravenous Oseltamivir Treatment of Severe Influenza B Virus Infection Requiring Organ Replacement Therapy.

Authors:  Katharina Karsch; Xi Chen; Oliver Miera; Björn Peters; Patrick Obermeier; Roland C Francis; Válerie Amann; Susanne Duwe; Pieter Fraaij; Alla Heider; Marcel de Zwart; Felix Berger; Albert Osterhaus; Brunhilde Schweiger; Barbara Rath
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-02       Impact factor: 2.441

6.  Zanamivir-resistant influenza viruses with a novel neuraminidase mutation.

Authors:  Aeron C Hurt; Jessica K Holien; Michael Parker; Anne Kelso; Ian G Barr
Journal:  J Virol       Date:  2009-07-29       Impact factor: 5.103

7.  Oseltamivir expands quasispecies of influenza virus through cell-to-cell transmission.

Authors:  Kotaro Mori; Kensaku Murano; Ryosuke L Ohniwa; Atsushi Kawaguchi; Kyosuke Nagata
Journal:  Sci Rep       Date:  2015-03-16       Impact factor: 4.379

8.  Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007-08 season.

Authors:  Adam Meijer; Angie Lackenby; Olav Hungnes; Bruno Lina; Sylvie van-der-Werf; Brunhilde Schweiger; Matthias Opp; John Paget; Jan van-de-Kassteele; Alan Hay; Maria Zambon
Journal:  Emerg Infect Dis       Date:  2009-04       Impact factor: 6.883

9.  Impact of emerging antiviral drug resistance on influenza containment and spread: influence of subclinical infection and strategic use of a stockpile containing one or two drugs.

Authors:  James M McCaw; James G Wood; Christopher T McCaw; Jodie McVernon
Journal:  PLoS One       Date:  2008-06-04       Impact factor: 3.240

10.  Estimating the fitness advantage conferred by permissive neuraminidase mutations in recent oseltamivir-resistant A(H1N1)pdm09 influenza viruses.

Authors:  Jeff Butler; Kathryn A Hooper; Stephen Petrie; Raphael Lee; Sebastian Maurer-Stroh; Lucia Reh; Teagan Guarnaccia; Chantal Baas; Lumin Xue; Sophie Vitesnik; Sook-Kwan Leang; Jodie McVernon; Anne Kelso; Ian G Barr; James M McCaw; Jesse D Bloom; Aeron C Hurt
Journal:  PLoS Pathog       Date:  2014-04-03       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.